Cardiovascular risk-benefit profile of sibutramine

AJ Scheen - American Journal of Cardiovascular Drugs, 2010 - Springer
Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an
antiobesity agent to reduce appetite and promote weight loss in combination with diet and …

WITHDRAWN—a resource for withdrawn and discontinued drugs

VB Siramshetty, J Nickel, C Omieczynski… - Nucleic acids …, 2016 - academic.oup.com
Post-marketing drug withdrawals can be associated with various events, ranging from safety
issues such as reported deaths or severe side-effects, to a multitude of non-safety problems …

Pharmacogenetics of drugs withdrawn from the market

W Zhang, MW Roederer, WQ Chen, L Fan… - …, 2012 - Taylor & Francis
The safety and efficacy of candidate compounds are critical factors during the development
of drugs, and most drugs have been withdrawn from the market owing to severe adverse …

Colorimetric and reverse fluorescence Dual-Signal Readout Immunochromatographic Assay for the sensitive determination of sibutramine

Y Gui, Y Zhao, P Liu, Y Wang, X Mao, C Peng… - ACS …, 2024 - ACS Publications
Later flow immunochromatographic assay has been widely used in clinical, environmental,
and other diagnostic applications owing to its high sensitivity and throughput. However, most …

Drug treatment for obesity in the post-sibutramine era

BMY Cheung - Drug safety, 2011 - Springer
Obesity is a major health problem worldwide. It is associated with cardiovascular diseases,
diabetes mellitus and decreased longevity. In managing obesity, diet and exercise are …

Sibutramine provokes apoptosis of aortic endothelial cells through altered production of reactive oxygen and nitrogen species

Y Morikawa, A Shibata, N Okumura, A Ikari… - Toxicology and Applied …, 2017 - Elsevier
Overdose administration of sibutramine, a serotonin-noradrenalin reuptake inhibitor, is
considered to elicit severe side effects including hypertension, whose pathogenic …

Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6* 6 allele

IC Hwang, JY Park, HY Ahn, KK Kim, HS Suh, KD Ko… - Clinica Chimica …, 2014 - Elsevier
Background Various cytochrome P450 isoforms modulate sibutramine activity and influence
sibutramine plasma levels and pharmacokinetics. However, there are no available data to …

Allele and genotype frequencies of CYP2B6 in a Turkish population

N Yuce-Artun, G Kose, HS Suzen - Molecular biology reports, 2014 - Springer
Increasing interest in cytochrome P450 2B6 (CYP2B6) genetic polymorphism was
stimulated by revelations of a specific CYP2B6 genotype significantly affecting the …

Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and …

R Nirogi, RC Palacharla, AR Mohammed… - Chemico-Biological …, 2015 - Elsevier
The objective of the study was to evaluate the metabolism dependent inhibition of CYP2B6
catalyzed bupropion hydroxylation in human liver microsomes by monoamine oxidase …

Simultaneous determination of sibutramine and its active metabolites in human plasma by LC‐MS/MS and its application to a pharmacokinetic study

JW Bae, CI Choi, CG Jang… - Biomedical …, 2011 - Wiley Online Library
ABSTRACT A simple and sensitive liquid chromatography–electrospray ionization–tandem
mass spectrometry (LC‐ESI‐MS/MS) technique was developed and validated for the …